Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study - PubMed (original) (raw)
Clinical Trial
. 2009 Dec;65(6):1070-6; discussion 1076-7.
doi: 10.1227/01.NEU.0000360128.03597.C7.
Collaborators, Affiliations
- PMID: 19934966
- DOI: 10.1227/01.NEU.0000360128.03597.C7
Clinical Trial
Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study
Arya Nabavi et al. Neurosurgery. 2009 Dec.
Abstract
Objective: To assess the feasibility of 5-aminolevulinic acid (5-ALA) fluorescence guidance for resection of recurrent malignant brain tumors.
Methods: In a multicenter prospective, single-arm, uncontrolled phase II study, 36 patients with recurrent glioma (World Health Organization grade III/IV) received 5-ALA before surgery. After microsurgical resection, biopsies from pathological and nonpathological areas (as identified under conventional white light) were obtained to determine the positive predictive value (PPV) of 5-ALA-induced tissue fluorescence in detecting tumors. Adverse events, neurological examinations, and survival data were documented for a minimal follow-up of 6 months.
Results: The patient-based PPV, defined as the percentage of patients showing positive tumor cell identification in all biopsies taken from areas of weak and strong fluorescence was 97.2% for pathological areas and 79.4% in nonpathological areas. Within areas of strong fluorescence, PPV was higher (91.7%) compared with that of weak fluorescence (82.4%). On the biopsy level for nonpathological-appearing tissue under white light (157 biopsies), the PPV of tissue fluorescence was 93.0% compared with 99.5% in pathological-appearing tissue (197 biopsies). Again, within areas of strong fluorescence, PPV was higher (96.9%) compared with that of weak fluorescence (90.3%). There were no adverse events pertaining to the study drug.
Conclusion: 5-ALA fluorescence has a high predictive value for the detection of tumor in recurrent gliomas. Prior treatment modalities, such as radiation or chemotherapy, do not invalidate the fluorescence guidance with 5-ALA. 5-ALA fluorescence guidance is an effective surgical adjunct in the surgery of recurrent malignant gliomas.
Similar articles
- A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.
Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, Berger MS. Lau D, et al. J Neurosurg. 2016 May;124(5):1300-9. doi: 10.3171/2015.5.JNS1577. Epub 2015 Nov 6. J Neurosurg. 2016. PMID: 26544781 Clinical Trial. - Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma.
Tsugu A, Ishizaka H, Mizokami Y, Osada T, Baba T, Yoshiyama M, Nishiyama J, Matsumae M. Tsugu A, et al. World Neurosurg. 2011 Jul-Aug;76(1-2):120-7. doi: 10.1016/j.wneu.2011.02.005. World Neurosurg. 2011. PMID: 21839963 - Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas.
Sanai N, Snyder LA, Honea NJ, Coons SW, Eschbacher JM, Smith KA, Spetzler RF. Sanai N, et al. J Neurosurg. 2011 Oct;115(4):740-8. doi: 10.3171/2011.6.JNS11252. Epub 2011 Jul 15. J Neurosurg. 2011. PMID: 21761971 - [Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant gliomas--a new treatment modality].
Cortnum S, Laursen R. Cortnum S, et al. Ugeskr Laeger. 2013 Feb 25;175(9):570-3. Ugeskr Laeger. 2013. PMID: 23608006 Review. Danish. - Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.
Tonn JC, Stummer W. Tonn JC, et al. Clin Neurosurg. 2008;55:20-6. Clin Neurosurg. 2008. PMID: 19248665 Review. No abstract available.
Cited by
- Fluorescence guidance in skull base surgery: Applications and limitations - A systematic review.
Suero Molina E, Bruneau M, Reuter G, Shahein M, Cavallo LM, Daniel RT, Kasper EM, Froelich S, Jouanneau E, Manet R, Messerer M, Mazzatenta D, Meling TR, Roche PH, Schroeder HW, Tatagiba M, Visocchi M, Prevedello DM, Stummer W, Cornelius JF; EANS Skull Base Section. Suero Molina E, et al. Brain Spine. 2024 Aug 29;4:103328. doi: 10.1016/j.bas.2024.103328. eCollection 2024. Brain Spine. 2024. PMID: 39309550 Free PMC article. Review. - A handheld device for intra-cavity and ex vivo fluorescence imaging of breast conserving surgery margins with 5-aminolevulinic acid.
Gibson C, Wang SC, Phoon A, Thalanki Anantha N, Ottolino-Perry K, Petropoulos S, Qureshi Z, Subramanian V, Shahid A, O'Brien C, Carcone S, Chung S, Tsui T, Son V, Sukhram M, Meng F, Done SJ, Easson AM, Cil T, Reedijk M, Leong WL, DaCosta RS. Gibson C, et al. BMC Biomed Eng. 2024 Jun 1;6(1):5. doi: 10.1186/s42490-024-00079-9. BMC Biomed Eng. 2024. PMID: 38822389 Free PMC article. - Evaluation of the Effect of Photodynamic Therapy on CAM-Grown Sarcomas.
Kerkhoff M, Grunewald S, Schaefer C, Zöllner SK, Plaumann P, Busch M, Dünker N, Ketzer J, Kersting J, Bauer S, Hardes J, Streitbürger A, Dirksen U, Hartmann W, Guder WK. Kerkhoff M, et al. Bioengineering (Basel). 2023 Apr 11;10(4):464. doi: 10.3390/bioengineering10040464. Bioengineering (Basel). 2023. PMID: 37106651 Free PMC article. - Review of Intraoperative Adjuncts for Maximal Safe Resection of Gliomas and Its Impact on Outcomes.
Chanbour H, Chotai S. Chanbour H, et al. Cancers (Basel). 2022 Nov 21;14(22):5705. doi: 10.3390/cancers14225705. Cancers (Basel). 2022. PMID: 36428797 Free PMC article. Review. - The diagnostic accuracy of intraoperative differentiation and delineation techniques in brain tumours.
Van Hese L, De Vleeschouwer S, Theys T, Rex S, Heeren RMA, Cuypers E. Van Hese L, et al. Discov Oncol. 2022 Nov 10;13(1):123. doi: 10.1007/s12672-022-00585-z. Discov Oncol. 2022. PMID: 36355227 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical